A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Subjects With Painful Diabetic Peripheral Neuropathy
Phase of Trial: Phase III
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Hepatocyte growth factor gene therapy (Primary)
- Indications Diabetic neuropathies
- Focus Registrational; Therapeutic Use
- Sponsors ViroMed; VM BioPharma
- 26 Jul 2017 Planned End Date changed from 1 Oct 2018 to 1 Jun 2019.
- 26 Jul 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Dec 2018.
- 27 Jun 2016 According to a VM BioPharma media release, the first patient has been dosed in this trial.